



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/427604/2021

European Medicines Agency decision P/0295/2021

of 11 August 2021

on the acceptance of a modification of an agreed paediatric investigation plan for potassium (chloride) / magnesium (sulphate heptahydrate) / procaine (hydrochloride) / xylitol (EMEA-001171-PIP01-11-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0295/2021

of 11 August 2021

on the acceptance of a modification of an agreed paediatric investigation plan for potassium (chloride) / magnesium (sulphate heptahydrate) / procaine (hydrochloride) / xylitol (EMA-001171-PIP01-11-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0140/2012 issued on 20 July 2012 and the decision P/0293/2016 issued on 4 November 2016,

Having regard to the application submitted by MIT Gesundheit GmbH on 22 March 2021 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 25 June 2021, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for potassium (chloride) / magnesium (sulphate heptahydrate) / procaine (hydrochloride) / xylitol, solution for injection, intracoronary use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to MIT Gesundheit GmbH, Thaerstraße 4a, 47533 - Kleve, Germany.

EMA/PDCO/210978/2021
Amsterdam, 25 June 2021

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001171-PIP01-11-M02

Scope of the application

Active substance(s):

Potassium (chloride) / magnesium (sulphate heptahydrate) / procaine (hydrochloride) / xylitol

Condition(s):

Cardioplegia

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Intracoronary use

Name/corporate name of the PIP applicant:

MIT Gesundheit GmbH

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, MIT Gesundheit GmbH submitted to the European Medicines Agency on 22 March 2021 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0140/2012 issued on 20 July 2012 and the decision P/0293/2016 issued on 4 November 2016.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 27 April 2021.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition:

Cardioplegia

2.1.1. Indication(s) targeted by the PIP

Cardioplegia

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	0	Not applicable.
Clinical	2	Study 1: Multicentre, multinational, patient blind, randomized, active controlled, non-inferiority study to explore the effects of potassium (chloride) / magnesium (sulphate heptahydrate) / procaine (hydrochloride) / xylitol on the protection of cardiac cells during the "ischaemic" period in order to allow a rapid and complete reversibility of the cardiac arrest when used during a cardiac surgical intervention under the assistance of a heart-lung machine in paediatric patients (SCT-Cpx-002) Study 2: Model-based bridging of clinical data to children and adolescents from 30 months to less than 18 years of age

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety or efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2025
Deferral for one or more studies contained in the paediatric investigation plan:	Yes